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Two primary functional assays grew out of the earlyYale University School of Medicine
studies on TAP. One assay measures peptide transportNew Haven, Connecticut 06510
across the ER membrane in streptolysin O–perme-
abilized cells (Neefjes et al., 1993; Androlewicz et al.,
1993) or microsomal preparations from mice or insect
Recognition of foreign and self-antigens by T cells re- cells that express recombinant TAP (Shepherd et al.,
quires the interaction of the T cell receptor with major 1993; Meyer et al., 1994). The second assay measures
histocompatibility complex (MHC) class I or class II mol- peptide binding to TAP (van Endert et al., 1994). The
ecules on the surface of the antigen-presenting cell. The key difference between these two assay systems is that
specificity of the interaction is provided by the antigenic peptide transport requires ATP, whereas peptide bind-
peptides that are bound to the MHC molecules. Gener- ing does not require ATP, and to measure peptide bind-
ally, MHC class I molecules present peptides that are ing ATP must be excluded. An important feature of the
derived from endogenous protein sources, while MHC peptide transport assay is the use of glycosylatable pep-
class II molecules present peptides from exogenous tides to measure directly the transport of peptides into
proteins. Many of the peptides presented by class I the ER. This technique (pioneered by Neefjes et al.,1993)
are derived from cytosolic proteins, and therefore these takes advantage of the natural glycosylation machinery
peptides must cross a lipid bilayer membrane in order located in the ER of cells. Peptides that contain an
to assemble with newly synthesized class I molecules N-linked glycosylation site (NXS or NXT), either naturally
in the lumen of the endoplasmic reticulum (ER) (see or engineered, become glycosylated upon entry into the
Figure 1). In contrast, MHC class II–associated peptides ER. This will occur as long as there is at least 1 aa
are not subjected to a similar requirement, as internal- C-terminal to the glycosylation site. This provides a di-
ized antigen in endosomes or lysosomes is topologically rect readout for the transport of radiolabeled peptides
equivalent to the class II molecules. To get peptides simply by measuring the level of peptide glycosylation
into the lumen of the ER, the cell has adapted a transport through binding to concanavalin A–Sepharose. How
molecule from the large family of transport proteins does the peptide transport assay relate to the peptide
called ATP-binding cassette (ABC) transporters (for re- binding assay in terms of TAP function? The data sug-
view see Higgins, 1992). Examples of well-characterized gest that peptide binding and peptide transport are
ABC transporters include P-glycoprotein (Chen et al., closely coupled. Indeed, when the same set of peptides
1986; Gros et al., 1986), the cystic fibrosis transmem- were tested in both assay systems the results were
brane conductance regulator (CFTR) (Riordan et al., remarkably similar (Androlewicz and Cresswell, 1994,
1989), and the STE 6 transporter in yeast (Kuchler et al., van Endert et al., 1995). Therefore, even though peptide
1989). The peptide transporter, called the transporter transport by TAP can be broken down into two steps,
associated with antigen processing (TAP), is composed i.e., peptide binding and peptide translocation, in func-
of two homologous proteins termed TAP1 and TAP2 tional assays the two steps are indistinguishable.
(Trowsdale et al., 1990; Spies et al., 1990; Deverson et With the role of TAP firmly established, the stage was
al., 1990; Monaco et al., 1990). Together, the TAP1/TAP2 set for investigation into the substrate specificity of TAP.
heterodimer forms a transport molecule that conserves The main issue here is to what degree does TAP select
the hallmarks of ABC transporters, i.e., the possession peptides that will be accessible to class I molecules.
of approximately twelve membrane-spanning domains The specificity issue can be further divided into two
and two hydrophilic ATP-binding domains (see Figure types: one is specificity for peptide length and the other
2). For ABC transporters, the hydrolysis of ATP is cou- is specificity for peptide sequence. The data has re-
pled to substrate transport. vealed a clear peptide length specificity, with TAP pre-
The critical role of TAP in class I antigen processing ferring peptides in the 8–12 aa range. TAP peptide se-
was established through the study of mutant cells that quence specificity appears to vary between species,
either lacked the TAP proteins (DeMars et al., 1985; with human TAP being the most promiscuous, mouse
Salter and Cresswell, 1986), or expressed a nonfunc- TAP the least promiscuous, and rat TAP lying some-
tional form of TAP1 or TAP2 (Ljunggren et al., 1989). where in between. The initial TAP sequence specificity
These cells possess impaired class I antigen processing studies focused on the effect that the C-terminal amino
and express low levels of class I molecules on their cell acid of the peptide has on selection by TAP. Mouse TAP
possesses a clear preference for peptides that containsurface. It was theorized that the transporter proteins
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Figure 1. Model of the MHC Class I Antigen
Processing Pathway
Protein antigens are degraded intosmall pep-
tides in the cell cytosol by the proteasome
complex. The peptides are transported into
the lumen of the ER by the transporters asso-
ciated with antigen processing (TAP) where
they assemble with newly synthesized MHC
class I heavy chains and b2-microglobulin
(b2m). Once assembled, the stable complex
of heavy chain, b2m, and peptide leaves the
ER and is expressed on the cell surface. Re-
cent data suggest that the class I heavy chain
and b2m associate with TAP prior to peptide
loading, and that the binding of peptide re-
leases the complex from TAP. (Illustration by
E. Hughes and M. Honey.)
hydrophobic (aliphatic and aromatic) C-terminal resi- regard to the sequence of the peptides that it bound
and transported. This conclusion was reached becausedues (Schumacher et al., 1994), whereas human TAP
does not possess a clear preference for any particular the majority of peptide variants, including ones made
up of predominantly alanine residues, were transportedC-terminal residue (Momburg et al., 1994a). Rat TAP
possesses both the hydrophobic as well as the nonspe- well by TAP. However, this study was restricted in that
variants from only three distinct class I epitopes werecific C-terminal residue specificity (Heemels et al., 1993;
Heemels and Ploegh, 1994). used and therefore the results may have been skewed
toward peptides that bind to class I and are transportedThe rat transporter is unique in the sense that different
alleles of TAP have functional consequences. Two dif- well by TAP. In a third study, which first described the
peptide binding assay for recombinant TAP in insectferent forms of the rat transporter are based on two
allelic versions of the rat TAP2 molecule. They differ by cell microsomes (van Endert et al., 1994), it was shown
that the affinity for TAP of a set of peptides in the 9–11approximately 25 aa, which are spread throughout
the membrane-spanning domains. The rat TAP1/TAP2a aa range varied widely. However, the number of peptides
used in this study was limited and no definite conclu-(cima) heterodimer resembles human TAP in that it does
not have a preference for a particular amino acid at the sions on the substrate specificity of TAP could be drawn.
All studies so far are in agreement with the observationC terminus, while the rat TAP1/TAP2u (cimb) heterodimer
resembles mouse TAP in that it prefers peptides with that blocked N- or C-terminal residues inhibit peptide
transport by TAP (Momburg et al., 1994a; Schumacherhydrophobic residues at the C terminus. This difference
results in distinct pools of peptides available for binding et al., 1994).
More definitive conclusions can be drawn from theto the rat class I molecule RT1Aa. Because the RT1Aa
molecule prefers peptides that possess basic residues length specificity studies that have been performed on
TAP. All studies are in close agreement that the minimalsuch as arginine at the C terminus (Powis et al., 1996),
it only becomes efficiently loaded in the presence of the length required for peptide transport by TAP is 7–9 aa
(Schumacher et al., 1994; Androlewicz and Cresswell,rat TAP1/TAP2a complex. The allelic forms of human
and mouse TAP have not yet been shown to have any 1994; Momburg et al., 1994b; van Endert et al., 1994;
Heemels and Ploegh, 1994). However, the maximalsignificant effect on peptide loading.
Several TAP functional studies were performed that length of peptides that can be transported by TAP is
not as clear cut. It was shown that at least one peptideanalyzed the role of amino acids at or near the N termi-
nus of the peptide. In one study (Momburg et al., 1994b), of 24 aa in length can effectively compete for reporter
peptide transport (CLIP, Androlewicz and Cresswell,peptides with amino acid substitutions at the N terminus
of an 8-mer peptide associated with mouse MHC class 1994). Generally, as peptide length increases beyond
the 8–12 aa optimal length (up to 40 aa so far tested),I molecules were analyzed for peptide transport by TAP.
It was concluded that amino acid substitutions at the N the capacity of the peptides to be transported or to
compete for peptide transport by TAP decreases (An-terminus had only a minor effect on peptide transport
across the three species tested. However, this study drolewicz and Cresswell, 1994; Momburg et al., 1994b;
Heemels and Ploegh, 1994). Of course, in some caseswas restricted by the number of different epitopes used
and the placement of the amino acid substitutions. In it is hard to distinguish between the effects of peptide
length and peptide sequence. In TAP peptide bindinganother study (Androlewicz and Cresswell, 1994), the
TAP transport capacity of a panel of peptide variants, studies (van Endert et al., 1994) it was shown that pep-
tides in the 9–16 aa range have high affinities for TAP,each derived from a natural epitope found associated
with MHC class I molecules, was analyzed. The conclu- while longer peptides have lower affinities. Overall, the
data on peptide length suggest that peptides longersion drawn was that human TAP was promiscuous with
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Figure 2. Structural Organization of TAP
The TAP transporter is a heterodimer of two
related proteins called TAP1 and TAP2. The
heterodimer consists of approximately
twelve hydrophobic membrane-spanning re-
gions, and two hydrophilic ATP-binding do-
mains. The TAP1/TAP2 dimeric structure is
required to form a functional transporter, i.e.,
TAP1 and TAP2 homodimers are not func-
tional. (Illustration by M. Honey.)
than 12 aa can be transported by TAP, but at a reduced that TAP transports peptides that are predisposed to
binding to class I molecules, caution should be takenefficiency. Interestingly, there appears tobe a difference
in peptide length preference between the rat cima and in the formation of any hard and fast rules. First, the
overall affinity of a given peptide for TAP is determinedcimb forms of TAP. The cima allele, which is the least
selective at the C terminus, is more selective with regard by a sum of the positive and negative interactions, and
any given negative interaction may be overcome by ato peptide length (not allowing peptides longer than 10
aa to pass) than the cimb allele (Heemels and Ploegh, stronger positive interaction elsewhere in the peptide.
Second, a significant number of HLA class I–binding1994).
A further step in the elucidation of TAP sequence motifs are not consistent with the TAP peptide-binding
motif. Namely, the motifs for HLA-A1, HLA-B7, HLA-B8,specificity has been taken with the recent identification
of a peptide-binding motif for human TAP (van Endert and other HLA-B and HLA-C alleles possess detrimental
amino acid residues as primary anchor sites. There is aet al., 1995). The investigators utilized the microsomal
peptide binding assay to measure the affinity for TAP particular propensity for the use of proline in position 2
as a primary anchor among the HLA-B alleles. Of course,of more than 250 peptides and peptide variants. From
these data, the investigators were able to identify a puta- one can argue that longer peptides that contain the
class I–binding epitopes are transported well by TAPtive peptide-binding motif for TAP. The nature of the
motif illustrates how the binding site for TAP differs from and then once inside the ER are trimmed to the appro-
priate size. In this case, it remains unclear as to whythe peptide-binding site of class I molecules. Particu-
larly, there are no single amino acids that serve as pri- the cell would impose another level of complexity to the
processing of certain class I epitopes. Third, it shouldmary anchor residues as described for the class I–asso-
ciated peptide motifs (for review see Rammensee et al., not be concluded that because a peptide possesses a
low affinity for TAP the peptide is not transported by1995). Rather, there are sets of amino acids at the N
terminus of the peptide, which TAP prefers. It appears TAP into the ER.
In summary, there is no question that TAP preselectsthat TAP prefers strongly hydrophobic residues in posi-
tion 3 (P3) of the peptide, and hydrophobic or charged peptides based upon peptide length. Peptides that are
the optimal size for binding to class I molecules, i.e.,residues in P2. However, aromatic or acidic residues in
P1, as well as proline in P1 or P2, have strong negative 8–12 aa, are transported with the greatest efficiency,
while longer peptides are transported at a reduced effi-effects on peptide affinity. Therefore, even though the
TAP motif is not as stringent as the HLA motifs, it ap- ciency. It is also clear that mouse and rat TAP preselect
peptides based upon the C-terminal residue; however,pears to be biased toward peptides that bind to HLA
molecules, as the specificity for both is dependent upon it is not clear how selective the human transporter is.
While a peptide-binding motif for human TAP has beenresidues at the N terminus. In fact, the investigators
show that the percentage of peptides with very low TAP described, its true extent and significance needs to be
explored in more detail. In humans, TAP plays the leastaffinities is significantly reduced in a group of naturally
processed peptides versus a group of random peptides. important role in determining which peptides are pre-
sented to T cells. Human TAP provides an abundantPeptide-binding motifs have not yet been identified for
the mouse or rat transporters; however, a recent study supply of peptides that are the optimal size for binding
to class I molecules, and it is the class I molecule thathas revealed that a prolyl residue in P3 has a strong
negative effect on peptide transport by mouse TAP (Nei- provides the ultimate specificity. Mouse and rat TAP
play a more important role in peptide selection due tosig et al., 1995).
While thenewly defined motif for human TAP suggests their preference for peptides that contain hydrophobic
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C termini. This is why mouse class I peptide-binding Heterodimers of class I heavy chain and b2-microglobu-
lin were shown to associate physically with TAP in coim-motifs contain hydrophobic anchor residues at the C
munoprecipitation experiments (Ortmann et al., 1994;terminus.
Suh et al., 1994). In addition, recent evidence suggestsNewdata with regard to substrate specificity and pep-
that class I interaction with TAP may be necessary totide binding to TAP have recently emerged. In one study,
load class I molecules with peptide (Grandea et al., 1995;four polymorphic amino acid residues that contribute to
Peace-Brewer et al., 1996). It is thought that the physicalthe specificity of the rat cima and cimb transporters were
interaction with TAP facilitates peptide loading by lo-identified (Momburg et al., 1996). Chimeric rat TAP2
calizing theclass I molecules to the site of peptide trans-molecules were made between segments of the TAP2a
location. Another possibility is that association withand TAP2u genes that encoded groups of the polymor-
class I enhances the rate of peptide transport by TAP.phic residues. These chimeric molecules were then ex-
Whatever the effect TAP/class I interaction has on pep-pressed along with rat TAP1 and assayed for peptide
tide loading, it does not appear to be critical becausetransport using iodinated peptides in which the C-termi-
class I molecules can be loaded effectively in TAP-nega-nal amino acid was varied. This allowed for the identifi-
tive cells when peptides are introduced into the ERcation of the particular polymorphic residues that con-
through a leader sequence (Anderson et al., 1991). Also,tribute to the C-terminal amino acid selectivity of rat
it appears that TAP efficiently transports peptides inTAP. Four polymorphic residues were identified in two
the absence of class I molecules (Grandea et al., 1995;separate regions of rat TAP2 (residues 217/218 and 374/
Meyer et al., 1994), suggesting that interaction with class380), which map to the two putative cytoplasmic loops
I molecules is not required for TAP to function. There isclosest to the hydrophilic C-terminal ATP-binding do-
evidence that another protein, of molecular massmain, and which appear to be located very close to the
48,000, associates with TAP (Ortmann et al., 1994;ER membrane. It is thought that the residues identified,
Peace-Brewer et al., 1996). The physiological role, if any,though spatially separate, come together to form part
of the 48 kDa protein remains to be determined, but theof the peptide-binding pocket.
evidence indicates that it may be involved in mediatingIn a second study (Nijenhuis et al., 1996), photoreac-
class I association with TAP (Grandea et al., 1995). Thus,tive peptide analogs were used to identify a segment
the number of players involved in the assembly andof human TAP1 that appears to be involved in peptide
loading of MHC class I molecules is increasing, and thebinding. The photoreactive peptides contained a photo-
true significance of their roles needs further study.reactive analog of phenylalanine. The photopeptides
These recent studies have provided information onwere transported normally by TAP, and therefore should
the molecular mechanism of peptide transport by TAP.interact with the same residues on TAP as wild-type
By identifying sites that are involved with peptide bind-peptide. The results of the photolabeling experiments
ing, and identifying molecules that associate with TAP,revealed that both TAP1 and TAP2 were labeled by the
we are closer to an understanding of how TAP works.photoreactive peptides (Nijenhuis et al., 1996), sug-
However, unanswered questions remain with regard togesting that the peptide-binding site of TAP is made up
the exact nature of the TAP–peptide interaction, the roleof elements of both TAP1 and TAP2 (Androlewicz et al.,
of associated proteins, and the mechanism of peptide1994). Individual chains expressed separately were not
translocation across the membrane. We await with inter-photolabeled, indicating that both TAP1 and TAP2 are
est future information that will provide insight into therequired to form a functional peptide-binding site. In
mechanism of action of this important transporter.addition, it was shown that both TAP1 and TAP2 chains
were labeled regardless of the positionof thephotoreac-
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